{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:58:07Z","timestamp":1793750287900,"version":"4.6.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Rocket Science Health"},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","award":["Tier II Chair in Nucleic Acid Bioengineering"],"award-info":[{"award-number":["Tier II Chair in Nucleic Acid Bioengineering"]}],"id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000245","name":"Michael Smith Health Research BC","doi-asserted-by":"publisher","award":["Scholar Award"],"award-info":[{"award-number":["Scholar Award"]}],"id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-03309-9","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T08:09:25Z","timestamp":1748333365000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Laminar fluid ejection device enables high yield and preservation of mRNA and SaRNA LNP formulations"],"prefix":"10.1038","volume":"15","author":[{"given":"Chia Hao","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irafasha C.","family":"Casmil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manu","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Rees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenza","family":"Enright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Allan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K.","family":"Blakney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"3309_CR1","doi-asserted-by":"publisher","unstructured":"Ashraf, M. U. et al. COVID-19 vaccines (revisited) and oral-mucosal vector system as a potential vaccine platform. Vaccines 9(2). https:\/\/doi.org\/10.3390\/vaccines9020171 (2021).","DOI":"10.3390\/vaccines9020171"},{"key":"3309_CR2","doi-asserted-by":"publisher","unstructured":"Lund, F. E. & Randall, T. D. Scent of a vaccine. Science 373(6553),  397\u2013399. https:\/\/doi.org\/10.1126\/science.abg9857 (2021).","DOI":"10.1126\/science.abg9857"},{"key":"3309_CR3","doi-asserted-by":"publisher","unstructured":"Afkhami, S. et al. Mar., Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2, Cell 185(5), 896\u2013915.e19. https:\/\/doi.org\/10.1016\/j.cell.2022.02.005 (2022).","DOI":"10.1016\/j.cell.2022.02.005"},{"key":"3309_CR4","doi-asserted-by":"publisher","unstructured":"Baldeon Vaca, G. et al. Sep., Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection, Sci. Adv., vol. 9, no. 38, p. eadh1655, (2023). https:\/\/doi.org\/10.1126\/sciadv.adh1655","DOI":"10.1126\/sciadv.adh1655"},{"key":"3309_CR5","doi-asserted-by":"publisher","unstructured":"Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R. & Blankschtein, D. mRNA vaccine delivery using lipid nanoparticles. Ther. Deliv. 7(5), 319\u2013334. https:\/\/doi.org\/10.4155\/tde-2016-0006 (2016).","DOI":"10.4155\/tde-2016-0006"},{"key":"3309_CR6","doi-asserted-by":"publisher","unstructured":"van Rijn, C. J. M. et al. Low energy nebulization preserves integrity of SARS-CoV-2 mRNA vaccines for respiratory delivery. Sci. Rep. 13(1), 8851. https:\/\/doi.org\/10.1038\/s41598-023-35872-4 (2023).","DOI":"10.1038\/s41598-023-35872-4"},{"key":"3309_CR7","doi-asserted-by":"publisher","unstructured":"Adam, R. E. & Zimm, B. H. Shear degradation of DNA*. Nucleic Acids Res. 4(5), 1513\u20131538. https:\/\/doi.org\/10.1093\/nar\/4.5.1513 (1977).","DOI":"10.1093\/nar\/4.5.1513"},{"key":"3309_CR8","doi-asserted-by":"publisher","unstructured":"Coleman, H. et al. Effect of mechanical stresses on viral capsid disruption during droplet formation and drying. Colloids Surf. B Biointerfaces. 233, 113661. https:\/\/doi.org\/10.1016\/j.colsurfb.2023.113661 (2024).","DOI":"10.1016\/j.colsurfb.2023.113661"},{"key":"3309_CR9","doi-asserted-by":"publisher","unstructured":"Hou, H. et al. Applications and research progress of traditional Chinese medicine delivered via nasal administration. Biomed. Pharmacother. 157, 113933. https:\/\/doi.org\/10.1016\/j.biopha.2022.113933 (Jan. 2023).","DOI":"10.1016\/j.biopha.2022.113933"},{"key":"3309_CR10","doi-asserted-by":"publisher","unstructured":"Bronsky, E. A. et al. May., A clinical trial of ipratropium bromide nasal spray in patients with perennial nonallergic rhinitis, J. Allergy Clin. Immunol., vol. 95, no. 5 Pt 2, pp. 1117\u20131122, (1995). https:\/\/doi.org\/10.1016\/s0091-6749(95)70215-6","DOI":"10.1016\/s0091-6749(95)70215-6"},{"key":"3309_CR11","doi-asserted-by":"publisher","unstructured":"Lam, J. K. W. et al. Transmucosal drug administration as an alternative route in palliative and end-of-life care during the COVID-19 pandemic. Adv. Drug Deliv Rev. 160, 234\u2013243. https:\/\/doi.org\/10.1016\/j.addr.2020.10.018 (2020).","DOI":"10.1016\/j.addr.2020.10.018"},{"key":"3309_CR12","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1109\/JTEHM.2024.3503498","volume":"12","author":"TM Morin","year":"2024","unstructured":"Morin, T. M. et al. Laminar fluid ejection for olfactory drug delivery: A proof of concept study. IEEE J. Transl Eng. Health Med. 12, 727\u2013738. https:\/\/doi.org\/10.1109\/JTEHM.2024.3503498 (2024).","journal-title":"IEEE J. Transl Eng. Health Med."},{"key":"3309_CR13","doi-asserted-by":"publisher","unstructured":"Lass, J. S., Sant, A. & Knoch, M. New advances in aerosolised drug delivery: vibrating membrane nebuliser technology. Expert Opin. Drug Deliv. 3(5), 693\u2013702. https:\/\/doi.org\/10.1517\/17425247.3.5.693 (2006).","DOI":"10.1517\/17425247.3.5.693"},{"key":"3309_CR14","doi-asserted-by":"publisher","unstructured":"Casmil, I. C. et al. Alphaviral backbone of self-amplifying RNA enhances protein expression and immunogenicity against SARS-CoV-2 antigen. Mol. Ther. 33(2), 514\u2013528. https:\/\/doi.org\/10.1016\/j.ymthe.2024.12.055 (2025).","DOI":"10.1016\/j.ymthe.2024.12.055"},{"key":"3309_CR15","doi-asserted-by":"publisher","unstructured":"Pietil\u00e4, M. K., Hellstr\u00f6m, K. & Ahola, T. Alphavirus polymerase and RNA replication. Virus Res. 234, 44\u201357. https:\/\/doi.org\/10.1016\/j.virusres.2017.01.007 (2017).","DOI":"10.1016\/j.virusres.2017.01.007"},{"key":"3309_CR16","doi-asserted-by":"publisher","unstructured":"Vogel, A. B. et al. Self-Amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses. Mol. Ther. 26(2), 446\u2013455. https:\/\/doi.org\/10.1016\/j.ymthe.2017.11.017 (2018).","DOI":"10.1016\/j.ymthe.2017.11.017"},{"key":"3309_CR17","doi-asserted-by":"publisher","unstructured":"Oda, Y. et al. Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2. Lancet Infect. Dis. 24(4), 341\u2013343. https:\/\/doi.org\/10.1016\/S1473-3099(24)00060-4 (2024).","DOI":"10.1016\/S1473-3099(24)00060-4"},{"key":"3309_CR18","doi-asserted-by":"publisher","unstructured":"Amplifying mRNA vaccine approved. Nat. Biotechnol. 42(1), 4\u20134. https:\/\/doi.org\/10.1038\/s41587-023-02101-2 (2024).","DOI":"10.1038\/s41587-023-02101-2"},{"key":"3309_CR19","doi-asserted-by":"publisher","unstructured":"Bathula, N. V. et al. Oct., Delivery vehicle and route of administration influences self-amplifying RNA biodistribution, expression kinetics, and reactogenicity. J. Controlled Release 374,  28\u201338. https:\/\/doi.org\/10.1016\/j.jconrel.2024.07.078 (2024).","DOI":"10.1016\/j.jconrel.2024.07.078"},{"key":"3309_CR20","doi-asserted-by":"publisher","unstructured":"Ly, H. H., Daniel, S., Soriano, S. K. V., Kis, Z. & Blakney, A. K. Optimization of lipid nanoparticles for saRNA expression and cellular activation using a design-of-experiment approach. Mol. Pharm. 19(6), 1892\u20131905. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c00032 (2022).","DOI":"10.1021\/acs.molpharmaceut.2c00032"},{"key":"3309_CR21","doi-asserted-by":"publisher","unstructured":"Popova, P. G., Lagace, M. A., Tang, G. & Blakney, A. K. Effect of in vitro transcription conditions on yield of high quality messenger and self-amplifying RNA. Eur. J. Pharm. Biopharm. 198, 114247. https:\/\/doi.org\/10.1016\/j.ejpb.2024.114247 (2024).","DOI":"10.1016\/j.ejpb.2024.114247"},{"key":"3309_CR22","doi-asserted-by":"publisher","unstructured":"Tenchov, R., Bird, R., Curtze, A. E. & Zhou, Q. Lipid nanoparticlesfrom liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano 15(11), 16982\u201317015. https:\/\/doi.org\/10.1021\/acsnano.1c04996 (2021).","DOI":"10.1021\/acsnano.1c04996"},{"key":"3309_CR23","doi-asserted-by":"publisher","unstructured":"Blakney, A. K.,  McKay, P. F., Yus, B. I., Aldon, Y. & Shattock, R. J. Inside out: Optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA, Gene Ther. 26(9), 363\u2013372. https:\/\/doi.org\/10.1038\/s41434-019-0095-2 (2019).","DOI":"10.1038\/s41434-019-0095-2"},{"key":"3309_CR24","doi-asserted-by":"publisher","unstructured":"Schoenmaker, L. et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int. J. Pharm. 601, 120586. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120586 (2021).","DOI":"10.1016\/j.ijpharm.2021.120586"},{"key":"3309_CR25","doi-asserted-by":"publisher","unstructured":"Rygg, A., Hindle, M. & Longest, P. W. Absorption and clearance of pharmaceutical aerosols in the human nose: Effects of nasal spray suspension particle size and properties. Pharm. Res. 33(4), 909\u2013921. https:\/\/doi.org\/10.1007\/s11095-015-1837-5 (2016).","DOI":"10.1007\/s11095-015-1837-5"},{"key":"3309_CR26","doi-asserted-by":"publisher","unstructured":"Roces, C. B. et al. Manufacturing considerations for the development of lipid nanoparticles using microfluidics. Pharmaceutics 12(11),  11. https:\/\/doi.org\/10.3390\/pharmaceutics12111095 (2020).","DOI":"10.3390\/pharmaceutics12111095"},{"key":"3309_CR27","doi-asserted-by":"publisher","unstructured":"Chen, H., Ren, X., Xu, S., Zhang, D. & Han, T. Optimization of lipid nanoformulations for effective mRNA delivery. Int. J. Nanomed. 17,  2893\u20132905. https:\/\/doi.org\/10.2147\/IJN.S363990 (2022)","DOI":"10.2147\/IJN.S363990"},{"issue":"9","key":"3309_CR28","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41434-019-0095-2","volume":"26","author":"AK Blakney","year":"2019","unstructured":"Blakney, A. K., McKay, P. F., Yus, B. I., Aldon, Y. & Shattock, R. J. Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of SaRNA. Gene Ther. 26(9), 363\u2013372. https:\/\/doi.org\/10.1038\/s41434-019-0095-2 (2019).","journal-title":"Gene Ther."},{"key":"3309_CR29","doi-asserted-by":"publisher","unstructured":"Kim, J. et al. Microfluidic platform enables shearless aerosolization of lipid nanoparticles for mRNA inhalation. ACS Nano. 18, 11335\u201311348. https:\/\/doi.org\/10.1021\/acsnano.4c00768 (2024).","DOI":"10.1021\/acsnano.4c00768"},{"key":"3309_CR30","doi-asserted-by":"publisher","unstructured":"Lavelle, E. C. & Ward, R. W. Mucosal vaccines\u2014fortifying the frontiers. Nat. Rev. Immunol. 22(4), 236\u2013250. https:\/\/doi.org\/10.1038\/s41577-021-00583-2 (2022).","DOI":"10.1038\/s41577-021-00583-2"},{"key":"3309_CR31","doi-asserted-by":"publisher","unstructured":"H\u1ed3, N. T. et al. Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: Pooled phase 1, 2, 3a and 3b randomized, controlled trials. Nat. Commun. 15(1), 4081. https:\/\/doi.org\/10.1038\/s41467-024-47905-1 (2024).","DOI":"10.1038\/s41467-024-47905-1"},{"key":"3309_CR32","doi-asserted-by":"publisher","unstructured":"Gao, M., Shen, X. & Mao, S. Factors influencing drug deposition in thenasal cavity upon delivery via nasal sprays. J. Pharm. Investig. 50(3), 251\u2013259. https:\/\/doi.org\/10.1007\/s40005-020-00482-z (2020).","DOI":"10.1007\/s40005-020-00482-z"},{"key":"3309_CR33","doi-asserted-by":"publisher","unstructured":"Kundoor, V. & Dalby, R. N. Effect of formulation- and administration-related variables on deposition pattern of nasal spray pumps evaluated using a nasal cast. Pharm. Res. 28(8), 1895\u20131904. https:\/\/doi.org\/10.1007\/s11095-011-0417-6 (2011).","DOI":"10.1007\/s11095-011-0417-6"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03309-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03309-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03309-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T08:09:26Z","timestamp":1748333366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03309-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3309"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-03309-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was funded in part by Rocket Science Health (RSH), and M.S., T.R., K.E., and N.A. are employees of RSH. The other authors have no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18507"}}